RP3 + atezolizumab + bevacizumab

RP3 + atezolizumab + bevacizumab is an investigational combination therapy being studied primarily for advanced, unresectable, or metastatic hepatocellular carcinoma (HCC)[3][5][7][9][10]. **RP3** is a genetically modified herpes simplex virus type 1 (HSV-1) oncolytic immunotherapy engineered to express GALV-GP R- protein, anti-CTLA-4 antibody-like molecule, CD40 ligand, and 4-1BB ligand[7]. This design enables RP3 to mediate direct tumor cell lysis and stimulate anti-tumor immunity within the tumor microenvironment, aiming to overcome resistance to immunotherapies. **Atezolizumab** is a monoclonal antibody checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), which helps activate T-cell mediated responses against tumor cells. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and limiting tumor blood supply. By combining RP3's oncolytic and immune-stimulatory effects with the proven activity of atezolizumab and bevacizumab, the regimen aims to enhance overall anti-tumor efficacy[3][5][7]. Currently, clinical trials are ongoing (Phase II) to determine safety and efficacy of this combination, particularly as first-line or second-line therapy for HCC[5][9][10]. Neither RP3 alone nor the triple combination has marketing approval for any indication.

Brand names

Tecentriq (atezolizumab)Avastin (bevacizumab)

Other names

RP3 + Tecentriq + Avastin